Researchers at the University of Pennsylvania School of Dental Medicine have developed a bioengineered chewing gum that reduced oral HPV levels by up to 93% in human saliva samples, while nearly eliminating two bacterial species directly linked to head and neck cancer. The study, published in Scientific Reports, represents a potential paradigm shift in oral cancer prevention — and Canadian dental professionals should understand what it means for chairside conversations, patient education, and the future of preventive oral medicine.
As of August 2026, oral cancers remain among the most challenging malignancies confronting dental professionals. HPV-related oropharyngeal squamous cell carcinoma has surged over the past two decades, now surpassing cervical cancer as the most common HPV-associated cancer in North America. For Canadian dentists performing routine oral cancer screenings — a standard-of-care expectation under the Royal College of Dental Surgeons of Ontario (RCDSO) and the Canadian Dental Association (CDA) — any tool that can reduce viral load in the oral cavity before malignancy develops is significant.
What the Research Found
The study was led by Dr. Henry Daniell, a professor at the University of Pennsylvania School of Dental Medicine, whose lab has spent over a decade engineering therapeutic proteins into plant-based delivery systems. According to the published findings, the team created a chewing gum infused with protegrin — an antimicrobial peptide — expressed through genetically engineered lettuce chloroplasts, then processed into a chewable tablet form.
The results, as reported in Scientific Reports, were striking:
- HPV reduction: Bean gum extracts reduced HPV levels by 93% in saliva samples and by 80% in oral rinse samples collected from patients with HPV-positive head and neck squamous cell carcinoma (HNSCC).
- Bacterial elimination: The gum brought levels of Porphyromonas gingivalis (Pg) and Fusobacterium nucleatum (Fn) — two bacterial species strongly associated with oral and colorectal cancers — down to near-zero levels.
- Selective action: The treatment preserved beneficial commensal bacteria in the oral microbiome, unlike broad-spectrum interventions such as radiation therapy or chlorhexidine rinses that indiscriminately damage healthy flora.
Why This Matters for Canadian Dental Practice
Head and neck cancers are the sixth most common cancer worldwide, and HPV-positive oropharyngeal cancers have been rising steadily in Canada. The Canadian Cancer Society estimates that oral cavity and pharyngeal cancers account for approximately 5,400 new diagnoses annually in Canada. Unlike many cancers where screening tools are well-established, oral HPV infection has no approved screening test — dental professionals rely on visual and tactile examinations during routine check-ups.
For dentists in Toronto and across the Greater Toronto Area (GTA), this research is relevant for several reasons:
- Patient education opportunities: Patients increasingly ask about HPV vaccination and oral cancer risk. Understanding this research helps you provide informed, evidence-based answers.
- Preventive care expansion: If a chewing gum-based therapeutic eventually reaches the market, it could become part of the preventive care conversation alongside fluoride, sealants, and oral hygiene instruction.
- Microbiome-aware treatment: The selective nature of the protegrin peptide — targeting pathogens while preserving commensals — aligns with the broader shift toward microbiome-conscious dentistry that many Canadian continuing education programs now emphasize.
The Science Behind Protegrin Delivery
According to the research team, protegrin is a naturally occurring antimicrobial peptide found in porcine leukocytes. Daniell's lab engineered lettuce plants to express this peptide within their chloroplasts — essentially turning plant cells into miniature pharmaceutical factories. The lettuce is then freeze-dried and processed into a gum or tablet form that releases the peptide during chewing.
This plant-based production method offers potential advantages over synthetic peptide manufacturing, including lower production costs and the ability to scale without the complex bioprocessing infrastructure that traditional biologics require. The researchers describe the approach as "molecular pharming" — a deliberate play on "farming" that reflects the agricultural production platform.
Pro Tip: When patients ask about oral cancer screening at their next check-up, use this research as a conversation starter about the importance of HPV vaccination. In Canada, the National Advisory Committee on Immunization (NACI) recommends HPV vaccination for all individuals aged 9 to 26, with catch-up vaccination available through age 45 in Ontario.
Where the Research Stands: Not Yet a Clinical Product
It is important to note that this chewing gum is not yet available as a commercial product. The study was conducted in vitro and on patient-derived samples — not as a randomized clinical trial of gum chewing in live patients over time. The researchers have described it as a potential adjunct therapy or preventive measure, but regulatory approval from bodies like Health Canada or the U.S. Food and Drug Administration (FDA) would require extensive clinical trials.
Canadian dental professionals should be cautious about presenting this as an imminent treatment option. The appropriate framing is: a promising early-stage research finding that demonstrates the potential for antimicrobial peptide-based oral therapeutics. It is not a replacement for current preventive measures, HPV vaccination, or regular oral cancer screening.
Pro Tip: Add a brief note about this research to your practice's patient education materials or newsletter. Framing it as "exciting research we're watching" positions your practice as informed and forward-thinking without overpromising.
The Broader Context: Oral Microbiome and Cancer Risk
The study's targeting of Porphyromonas gingivalis and Fusobacterium nucleatum is significant beyond HPV. Both bacteria have been independently linked to cancer risk in multiple studies:
- P. gingivalis is the primary pathogen in chronic periodontitis and has been associated with pancreatic cancer, esophageal cancer, and colorectal cancer in epidemiological studies.
- F. nucleatum has been found in elevated levels within colorectal tumour tissue and is increasingly recognized as a potential biomarker and contributor to tumour progression.
For dental professionals, this reinforces the clinical significance of periodontal disease management — not just for oral health, but as part of a systemic health conversation. The emerging links between the oral microbiome and systemic disease are reshaping how both medicine and dentistry approach prevention.
What Canadian Dentists Should Do Now
While this particular therapeutic is years from clinical availability, the research has immediate practical implications:
- Reinforce oral cancer screening protocols. The RCDSO expects dentists to perform systematic oral cancer screenings as part of comprehensive examinations. This research underscores why.
- Discuss HPV vaccination with patients. Ontario provides publicly funded HPV vaccination through school-based programs. Adult patients who missed the school program can access catch-up doses through public health units or pharmacies.
- Stay current on microbiome research. The CDA and ODA regularly publish continuing education resources on emerging oral-systemic health connections.
- Document risk factors. Note HPV-related risk factors (tobacco use, alcohol consumption, sexual health history where appropriate) in patient charts to support targeted screening conversations.
EBIKO Dental will continue monitoring this research as it progresses toward clinical trials and potential therapeutic applications.
Frequently Asked Questions
Q: Can patients buy this cancer-fighting chewing gum now?
No. The bioengineered chewing gum developed at the University of Pennsylvania is a research product, not a commercially available therapeutic. It has not been approved by Health Canada or any other regulatory body. Clinical trials in live patients would need to be completed before any commercial product could be developed.
Q: How does oral HPV relate to dental practice in Canada?
Oral HPV infection is the primary cause of HPV-positive oropharyngeal cancer, which has been rising in Canada. Dentists perform oral cancer screenings during routine examinations and are often the first to detect suspicious lesions. The RCDSO expects comprehensive oral cancer screening as part of standard care.
Q: Should dental practices in Ontario be offering HPV testing to patients?
There is currently no Health Canada-approved point-of-care HPV screening test for dental office use. Dental professionals should continue performing visual and tactile oral cancer screenings and refer patients with suspicious findings to oral medicine specialists or their physician for further evaluation, including biopsy when indicated.